Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia
Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Jean‐Pierre J. Issa(Coriell Institute For Medical Research), Jörge E. Cortes(Augusta University Health), Stefan Faderl(The University of Texas MD Anderson Cancer Center), Alessandra Ferrajoli(The University of Texas MD Anderson Cancer Center), Yasuhiro Oki(Unknown), Jan Davis(Leukemia Research Foundation), Xuelin Huang(The University of Texas MD Anderson Cancer Center), Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), Francis J. Giles(National University of Ireland), Zeev Estrov(The University of Texas MD Anderson Cancer Center), William G. Wierda(University of Maryland, Baltimore), Susan O’Brien(University of California, Irvine), Jianqin Shan(The University of Texas MD Anderson Cancer Center), Farhad Ravandi(The University of Texas MD Anderson Cancer Center), Hussain I. Saba(University of Tampa), Carlos E. Bueso‐Ramos(The University of Texas MD Anderson Cancer Center)
Cited by 691
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Incidence and functional consequences of <i>hMLH1</i> promoter hypermethylation in colorectal carcinoma
|Proceedings of the National Academy of Sciences|1998|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k